Krystal Biotech (NASDAQ:KRYS) EVP Sells $193,903.26 in Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) EVP John Charles Thomas sold 642 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total value of $193,903.26. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Krystal Biotech Trading Up 1.3%

Shares of NASDAQ:KRYS traded up $3.95 during trading on Wednesday, reaching $306.63. 144,305 shares of the company traded hands, compared to its average volume of 294,027. Krystal Biotech, Inc. has a 52-week low of $123.03 and a 52-week high of $319.48. The firm has a market capitalization of $9.04 billion, a price-to-earnings ratio of 40.99 and a beta of 0.50. The business’s fifty day moving average is $275.34 and its 200-day moving average is $259.63.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The company had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million. On average, sell-side analysts predict that Krystal Biotech, Inc. will post 7.98 earnings per share for the current fiscal year.

Institutional Trading of Krystal Biotech

A number of hedge funds have recently modified their holdings of KRYS. Bessemer Group Inc. increased its stake in shares of Krystal Biotech by 106.9% in the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after acquiring an additional 77 shares in the last quarter. Sound Income Strategies LLC boosted its stake in Krystal Biotech by 1,270.0% during the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after acquiring an additional 127 shares in the last quarter. Western Wealth Management LLC bought a new stake in Krystal Biotech during the first quarter worth about $34,000. Greenline Wealth Management LLC purchased a new stake in Krystal Biotech in the fourth quarter worth about $34,000. Finally, Danske Bank A S bought a new position in shares of Krystal Biotech during the third quarter valued at approximately $35,000. Institutional investors own 86.29% of the company’s stock.

Analysts Set New Price Targets

KRYS has been the subject of several research reports. Citigroup upped their price objective on shares of Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Weiss Ratings raised shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, April 9th. Jefferies Financial Group increased their price target on shares of Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Evercore restated an “outperform” rating and issued a $300.00 price objective on shares of Krystal Biotech in a report on Tuesday, May 5th. Finally, Zacks Research cut Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Ten investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Krystal Biotech has a consensus rating of “Moderate Buy” and an average price target of $324.11.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.